Patterns of treatment failure for PD-(L)1 refractory extensive-stage small cell lung cancer in continued PD-(L)1 treatment

Background: Although immunotherapy greatly extends overall survival (OS) of patients with extensive-stage small cell lung cancer (ES-SCLC), a number of patients develop immunotherapy resistance (IR). Patterns of failure in ES-SCLC are not clarified. Our study aims to explore the clinical pattern of...

Full description

Bibliographic Details
Published in:	Translational Oncology
Main Authors:	Li Liu, Tong Liu, Xingwen Wang, Jianbo Wang, Jun Wang, Meng Yuan, Yunxin Yang, Yingying Zhang, Hang Wang, Pingping Hu, Jiandong Zhang
Format:	Article
Language:	English
Published:	Elsevier 2023-07-01
Subjects:	Extensive-stage small cell lung cancer (ES-SCLC) Immunotherapy Patterns of failure
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523323000736

Similar Items

Efficacy of PD-(L)1 inhibitors plus anlotinib in the second-line treatment of extensive-stage small cell lung cancer
by: Jian Zhang, et al.
Published: (2025-07-01)

Molecular subtyping dictates therapeutic response to anti-PD-L1 immunotherapy in ES-SCLC
by: Qianqian Zhang, et al.
Published: (2025-05-01)

Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China
by: Zhou D, et al.
Published: (2023-11-01)

Camrelizumab, an Anti‐PD‐1 Monoclonal Antibody, Plus Carboplatin and Nab‐Paclitaxel as First‐Line Setting for Extensive‐Stage Small‐Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis
by: Jia Yu, et al.
Published: (2025-08-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

Phase III, multicenter, randomized trial of 45 Gy versus 30 Gy thoracic radiation for extensive‐stage small cell lung cancer (ES‐SCLC): Study protocol
by: Lei Deng, et al.
Published: (2024-04-01)

Addition of thoracic radiotherapy to a PD-L1 inhibitor plus chemotherapy regimen delays brain metastasis onset in extensive-stage small cell lung cancer patients without baseline brain metastasis
by: Baiyang Huang, et al.
Published: (2025-03-01)

Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report
by: Zhang C, et al.
Published: (2023-09-01)

Real-world data on immunotherapy combined with chemotherapy in elderly patients with extensive-stage small cell lung cancer
by: Ke Zhao, et al.
Published: (2025-03-01)

Clinical impact of first‐line PD‐1 or PD‐L1 inhibitors combined with chemotherapy in extensive‐stage small cell lung cancer patients: A real‐world multicenter propensity score‐matched study
by: Jingyuan Xie, et al.
Published: (2023-05-01)

Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive‐stage small‐cell lung cancer patients (DURABLE study)
by: Bo Zhang, et al.
Published: (2023-12-01)

Efficacy and safety of first-line chemotherapy combined with immune checkpoint inhibitors for extensive-stage small cell lung cancer patients: a real-world propensity score matching study
by: Bin Jia, et al.
Published: (2025-08-01)

Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): a phase II trialResearch in context
by: Dawei Chen, et al.
Published: (2024-09-01)

ES-SCLC Patients with PD-L1<sup>+</sup> CTCs and High Percentages of CD8<sup>+</sup>PD-1<sup>+</sup>T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment
by: Anastasia Xagara, et al.
Published: (2024-01-01)

First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial
by: Ying Cheng, et al.
Published: (2025-08-01)

Unexpected response with toripalimab in a patient with extensive-stage small-cell lung cancer: A case report
by: Zhen Cheng, et al.
Published: (2025-03-01)

Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing
by: Yena Gan, et al.
Published: (2023-07-01)

Extensive Stage Small-Cell Lung Cancer with Cystic Brain Metastases: A Report of Two Cases
by: Cai F, et al.
Published: (2024-03-01)

First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis
by: Lidan Yi, et al.
Published: (2024-07-01)

Correlation between immune-related adverse events and efficacy of PD-(L)1 inhibitors in small cell lung cancer: a multi-center retrospective study
by: Jian Zhang, et al.
Published: (2024-06-01)

A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer
by: Ping-Chih Hsu, et al.
Published: (2024-04-01)

Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives
by: Shuang Zhang, et al.
Published: (2023-04-01)

Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients
by: Martina Lorenzi, et al.
Published: (2024-01-01)

Long-term, 13-year survival after immune cell therapy combined with chemotherapy for extensive-stage small-cell lung cancer: a case report
by: Tong Liu, et al.
Published: (2024-06-01)

Anlotinib plus platinum‐etoposide as a first‐line treatment for extensive‐stage small cell lung cancer: A single‐arm trial
by: Pengbo Deng, et al.
Published: (2022-10-01)

Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review
by: Xu Zhang, et al.
Published: (2022-11-01)

The Efficacy and Safety of Albumin‐Bound Paclitaxel Combined With Anlotinib and PD‐1/L1 Inhibitors For Treating Patients With Extensive‐Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort Study
by: Xiaobing Li, et al.
Published: (2024-12-01)

Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis
by: Arani Sathiyapalan, et al.
Published: (2022-11-01)

Immune Activation Effects at Different Irradiated Sites and Optimal Timing of Radioimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer: a Real-World Analysis
by: Min Wu, et al.
Published: (2023-09-01)

Real‐World Response and Survival Outcomes and Treatment Patterns in Patients With Extensive Stage Small‐Cell Lung Cancer Receiving Third‐Line Treatment
by: Jair Bar, et al.
Published: (2025-08-01)

Heterogeneity between subgroups of first-line chemoimmunotherapy for extensive-stage small cell lung cancer patients: a meta-analysis and systematic review
by: Wenwen Kang, et al.
Published: (2024-10-01)

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
by: Yuanbin Chen, MD, PhD, et al.
Published: (2022-06-01)

Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study
by: David E. Dawe, et al.
Published: (2023-09-01)

Population Pharmacokinetics and Exposure–Response Analysis of Serplulimab in Small Cell Lung Cancer Patients
by: Kun Wang, et al.
Published: (2025-09-01)

First-line chemotherapy with tislelizumab for patients with extensive-stage small cell lung cancer: a cost-effectiveness analysis
by: Rong Long, et al.
Published: (2024-12-01)

Rare Combined Small Cell Lung Carcinoma and Lung Squamous Cell Carcinoma Response to PD-1 Inhibitor as Third-Line Therapy: A Case Report
by: Liu Z, et al.
Published: (2023-02-01)

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
by: Ke Wang, et al.
Published: (2025-01-01)

Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer
by: Jianfeng Peng, et al.
Published: (2023-07-01)

Meta‐analysis of PD‐(L)1 inhibitor plus chemotherapy versus chemotherapy as first‐line treatment in extensive‐stage small‐cell lung cancer
by: Jiangyue Lu, et al.
Published: (2023-09-01)

Exploring the prognostic impact of differences in treatment strategies for SCLC with different histologies and prognostic factors for C-SCLC: A SEER population-based study
by: Jiaping Liu, et al.
Published: (2024-06-01)